Physician profile
Meredith Asper
NPI 1881243251
$2,445.89
in general payments reported to CMS, 2019-2025
18 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $814 · 2023: $411 · 2024: $745 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Consulting Fee: $620 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.07 |
| Consulting Fee | $620.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $741.24 | 2022-2023 | Cabometyx |
| Gilead Sciences, INC. | $642.95 | 2023-2024 | Trodelvy |
| Seagen INC. | $170.22 | 2023 | Padcev |
| Myriad Genetic Laboratories, INC. | $145.88 | 2025 | Myrisk |
| Incyte Corporation | $124.80 | 2024 | Jakafi |
| Astrazeneca Pharmaceuticals Lp | $124.76 | 2021 | |
| Glaxosmithkline, LLC. | $121.41 | 2021 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2022 | |
| Pfizer INC. | $61.36 | 2025 | |
| Merck Sharp & Dohme LLC | $35.33 | 2023 | Keytruda, Lynparza |
| Genmab U.S., INC. | $34.28 | 2023 | Tivdak |
| Daiichi Sankyo INC. | $24.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.13 | 2025 | |
| Blue Earth Diagnostics | $23.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.49 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $20.98 | 2023 | Zoladex |
| Pharmacosmos Therapeutics INC. | $15.41 | 2023 | Monoferric |
| Amgen INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Asper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.